Biotechnology company Seattle Genetics Inc. (SGI) is now largely in the hands of well-known biotech investors and the $200 million market cap company could soon find itself the target of offers.In fact, a corporate development officer at an East Coast biotech company said the type of drugs SGI is developing–monoclonal antibody based therapeutics, which are used to treat cancer–are in high demand right now. “It is the technology du jour,'” he said. The development officer, who requested anonymity, said he frequently hears “good buzz” about SGI from other companies and from investors, and that he expects more consolidation in the cancer treatment space.
To read the entire story, you must be logged in.
Please log in now or register with us.
